TREATMENT FOR CORONARY HEART DISEASE COMPLICATED BY CHRONIC HEART FAILURE WITH A LOW LEFT VENTRICULAR EJECTION FRACTION

Download full text PDF
Issue: 
8
Year: 
2017

E. Ryabikhin, Candidate of Medical Sciences; M. Mozheiko, MD; Yu. Krasilnikova; S. Savicheva; M. Potanina Yaroslavl Regional Clinical Hospital for War Veterans – «Zdorovoe Dolgolenie» (Healthy Longevity) International Center

The safety and efficiency of nicorandil therapy during optimal medical therapy and its impact on left ventricular (LV) remodeling and function were evaluated in patients with stable ischemic heart disease complicated by chronic heart failure with a low LV ejection fraction.
Keywords: 
cardiology
therapy
coronary heart disease
chronic heart failure

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Bojtsov S.A., Chuchalin A.G. Dispansernoe nabljudenie za bol'nymi hronicheskimi neinfektsionnymi zabolevanijami i patsientov s vysokim riskom ih razvitija. Metodicheskie rekomendatsii / M.: 2014, 112.
  2. Shal'nova S.A., Oganov R.G., Steg F.G. i dr. Ishemicheskaja bolezn' serdtsa. Sovremennaja real'nost' po dannym vsemirnogo registra CLARIFY // Kardiologija. – 2013; 8: 28–33.
  3. Montalescot G., Sechtem U., Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force of the European Society of Cardiology // Eur. Heart J. – 2013; 34 (38): 2949–3003.
  4. Cleland J., Swedberg K., Follath F. et al. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis // Eur. Heart J. – 2003; 24 (5): 442–63.
  5. Belenkov Ju.N., Mareev V.Ju., Ageev F.T. i dr. Pervye rezul'taty natsional'nogo epidemiologicheskogo issledovanija – epidemiologicheskoe obsledovanie bol'nyh HSN v real'noj klinicheskoj praktike (po obraschaemosti) – EPOHA–O–HSN // Serdechnaja nedostatochnost'. – 2003; 4 (3): 116–21.
  6. Oganov R.G., Mamedov M.N. Natsional'nye klinicheskie rekomendatsii VNOK / M.: Silitseja-Poligraf, 2009; 528 s.
  7. Shaw L., Berman D., Maron D. et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and AggressiveDrug Evaluation (COURAGE) trial nuclear substudy // Circulation. – 2008; 117 (10): 1283–91.
  8. Oganov R.G., Bojtsov S.A., Ageev F.T. i dr. Natsional'nye rekomendatsii VNOK // Kardiovask. ter. i profilakt. – 2011; 10 (6 Pril. 2): 1–64.
  9. IONA Study Grup. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomized trial // Lancet. – 2002; 359 (9314): 1269–75.
  10. Horinaka S., Yabe A., Yagi H. et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study // Circ. J. – 2010; 74 (3): 503–9.
  11. Ishihara M., Sato H., Tateishi H. et al. Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and longterm prognosis // J. Am. Coll. Cardiol. – 1997; 30 (4): 970–5.
  12. Rezkalla S., Kloner R. Preconditioning in humans // Heart Fail. Rev. – 2007; 12 (3–4): 201–6.
  13. Vatutin N.T., Kalinkina N.V., Kolesnikov V.S. i dr. Fenomen prekonditsionirovanija // Serdtse. – 2013; 12 (4): 199–206.
  14. Bulahova E.Ju., Korennova O.Ju., Kondrasheva M.N. i dr. Klinicheskie preimuschestva terapii nikorandilom v sravnenii s izosorbid-5-mononitratom u bol'nyh IBS // Serdtse. – 2013; 12 (2): 83–7.
  15. Sizova Zh.M., Zaharova V.L., Shamieva E.S. i dr. Vozmozhnosti nikorandila v korrektsii koronarnogo rezerva i endotelial'noj disfunktsii u bol'nyh ishemicheskoj bolezn'ju serdtsa // Serdtse. – 2013; 12 (2): 75–82.
  16. Horinaka S. Use of nicorandil in cardiovascular disease and its optimization // Drugs. – 2011; 71 (9): 1105–19.
  17. Rjabihin E.A., Mozhejko M.E., Krasil'nikova Ju.A. Effektivnost' i bezopasnost' dlitel'noj terapii nikorandilom bol'nyh stabil'noj stenokardiej // Serdtse. – 2014; 13 (3): 151–5.
  18. Kinoshita M., Sakai K. Pharmacology and therapeutic effects of nicorandil // Cardiovasc. Drugs Ther. – 1990; 4 (4): 1075–88.
  19. Meany T., Richardson P., Camm A. et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris // Am. J. Cardiol. – 1989; 63 (21): 66–70.
  20. Yang J., Zhang J., Cui W. et al. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention // Anatol. J. Cardiol. – 2015; 15 (2): 125–31.
  21. Airaksinen K., Huikuri H. Antiarrhythmic effect of repeated coronary occlusion during balloon angioplasty // J. Am. Coll. Cardiol. – 1997; 29 (5): 1035–8.
  22. Sakamoto T., Kaikita K., Miyamoto S. et al. Effects of nicorandil on endogenous fibrinolytic capacity in patients with coronary artery disease // Circ. J. – 2004; 68 (3): 232–5.
  23. Izumiya Y., Kojima S., Araki S. et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris // Atherosclerosis. – 2011; 214 (2): 415–21.
  24. Markham A., Plosker G., Goa K. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects // Drugs. – 2000; 60 (4): 955–74.
  25. Sekiya M., Sato M., Funada J. et al. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis // J. Cardiovasc. Pharmacol. – 2005; 46 (1): 63–7.
  26. Kasama S., Toyama T., Sumino H. et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction // J. Nucl. Med. – 2007; 48 (10): 1676–82.